Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

T. Sumiyoshi*, M. Matsui, S. Nohara, I. Yamashita, M. Kurachi, C. Sumiyoshi, K. Jayathilake, H. Y. Meltzer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

188 Scopus citations


Objective: The goal of this study was to evaluate the effects of the addition of tandospirone, a serotonin-1A (5-HT1A) agonist, to ongoing treatment with typical antipsychotic drugs, on two cognitive domains that are relevant to functional outcome in patients with schizophrenia. Method: Twenty-six patients with schizophrenia who were receiving stable doses of typical antipsychotics were randomly assigned to adjunctive treatment with 30 mg/day of tandospirone or placebo for 6 weeks. Executive function and verbal memory as well as psychopathology were assessed at baseline and after 6 weeks. Results: Both cognitive measures improved significantly in the patients who received tandospirone; subjects who did not receive tandospirone showed no change. There was no significant change in psychopathology ratings in either group. Conclusions: The results suggest the usefulness of 5-HT1A agonists for enhancing some types of cognitive performance and possibly social and work function in patients with schizophrenia.

Original languageEnglish (US)
Pages (from-to)1722-1725
Number of pages4
JournalAmerican Journal of Psychiatry
Issue number10
StatePublished - Oct 14 2001

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment'. Together they form a unique fingerprint.

Cite this